Overview

A class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws.  The Lifecore class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the “Class Period”).  Investors have until September 27, 2024, to seek appointment as lead plaintiff of the Lifecore class action lawsuit.

Lifecore, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally.  The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterials markets, and licenses technology applications to partners.

The Lifecore class actions lawsuit alleges that in September 2022, Lifecore began reporting various issues concerning the internal controls over its financial reporting.  The lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lifecore maintained deficient internal controls over financial reporting; (2) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (3) Lifecore’s purported remediation efforts with respect to the foregoing deficiencies were ineffective; (4) all of the foregoing impaired Lifecore’s ability to timely file periodic reports with the U.S. Securities and Exchange Commission in compliance with NASDAQ listing requirements; (5) accordingly, the Company’s financial position and/or prospects were materially overstated; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as a lead plaintiff in the Lifecore lawsuit is September 27, 2024.